Hanoch Rappaport
Chief Executive Officer at Provident Fund of the Hebrew University of Jerusalem Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ofer Goldberg | M | 52 |
BioCancell Therapeutics, Inc.
 BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 13 years |
| Yosi Ben-Dov | M | - |
The Hebrew University of Jerusalem
| 10 years |
| Hermona Soreq | M | - |
The Hebrew University of Jerusalem
| - |
| Jonathan Burgin | M | 63 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 13 years |
| Alexander Levitzki | M | - |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel.
The Hebrew University of Jerusalem
| 47 years |
| Bilha Shapira | F | 71 |
The Hebrew University of Jerusalem
| 15 years |
| Uzi Vardi Zer | M | 85 |
The Hebrew University of Jerusalem
| - |
| Miriyam Katz | F | 73 |
The Hebrew University of Jerusalem
| 9 years |
| Tamar Yassur | F | 58 |
The Hebrew University of Jerusalem
| - |
| Yaron Ilan | M | 64 |
The Hebrew University of Jerusalem
| 26 years |
| Isaiah Arkin | M | - |
The Hebrew University of Jerusalem
| 15 years |
| Raphael Gorodetsky | M | - |
The Hebrew University of Jerusalem
| - |
| Abraham Israeli | M | 70 |
The Hebrew University of Jerusalem
| 28 years |
| David Kolitz | M | 81 |
The Hebrew University of Jerusalem
| - |
| Marta Weinstock-Rosin | F | - |
The Hebrew University of Jerusalem
| - |
| Naomi Chazan | F | - |
The Hebrew University of Jerusalem
| - |
| Itzhak Galnoor | M | - |
The Hebrew University of Jerusalem
| - |
| Sarah Ozacky-Lazar | M | - |
The Hebrew University of Jerusalem
| 19 years |
| Billy Shapira | F | - |
The Hebrew University of Jerusalem
| - |
| Doron Shorrer | M | 41 |
The Hebrew University of Jerusalem
| - |
| Zeev Rotstein | M | 73 |
The Hebrew University of Jerusalem
| - |
| Saul Yedgar | M | 82 |
The Hebrew University of Jerusalem
| 42 years |
| Adi Ben-Nun | M | - |
The Hebrew University of Jerusalem
| 30 years |
| Zvi Wiener | M | - |
The Hebrew University of Jerusalem
| - |
| Dan Yitzhak Gillerman | M | 80 |
The Hebrew University of Jerusalem
| - |
| Ilan Kremer | M | 57 |
The Hebrew University of Jerusalem
| 13 years |
| Amotz Agnon | M | 69 |
The Hebrew University of Jerusalem
| - |
| Eugene Kandel | M | - |
The Hebrew University of Jerusalem
| 27 years |
| Nechama Tzivin | F | 70 |
The Hebrew University of Jerusalem
| - |
| Shimon Shitrit | M | 78 |
The Hebrew University of Jerusalem
| 28 years |
| Zvi Ioav Cabantchik | M | - |
The Hebrew University of Jerusalem
| 45 years |
| Itamar Borowitz | M | 80 |
The Hebrew University of Jerusalem
| - |
| Michal Gilon Ohev Zion | M | 46 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 11 years |
| Maya Liquornik | F | 68 |
The Hebrew University of Jerusalem
| - |
| Udi Nissan Nisan | M | 55 |
The Hebrew University of Jerusalem
| - |
| Anwar Mahmoud Rayan | M | - |
The Hebrew University of Jerusalem
| - |
| Jacob Avraham Neuman | M | 75 |
The Hebrew University of Jerusalem
| 42 years |
| Gordon Brian Stephen Hausmann | M | 77 |
The Hebrew University of Jerusalem
| - |
| Taher Nassar | M | - |
The Hebrew University of Jerusalem
| - |
| Aharon M. Eyal | M | - |
The Hebrew University of Jerusalem
| - |
| Moshe Vidman | M | 80 |
The Hebrew University of Jerusalem
| 29 years |
| I. Edelson | M | 64 |
The Hebrew University of Jerusalem
| - |
| Leon Recanati | M | 76 |
The Hebrew University of Jerusalem
| - |
| Gurion Meltzer | M | - |
The Hebrew University of Jerusalem
| - |
| David Avnir | M | - |
The Hebrew University of Jerusalem
| - |
| Aharon Schwartz | M | 80 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 13 years |
| Yehoshua Gleitman | M | 74 |
The Hebrew University of Jerusalem
| 5 years |
| Uzi Rosen | M | 80 |
The Hebrew University of Jerusalem
| - |
| Yair Seroussi | M | 68 |
The Hebrew University of Jerusalem
| - |
| Isaac Manor | M | 83 |
The Hebrew University of Jerusalem
| - |
| Harel Beit On | M | 64 |
The Hebrew University of Jerusalem
| 6 years |
| Erel Margalit | M | 63 |
The Hebrew University of Jerusalem
| - |
| Richard Ziman | M | 81 |
The Hebrew University of Jerusalem
| - |
| Giora Yaron | M | 75 |
The Hebrew University of Jerusalem
| - |
| Martin S. Gerstel | M | 82 |
The Hebrew University of Jerusalem
| - |
| Jonathan Brodie | M | 67 |
The Hebrew University of Jerusalem
| - |
| Ron Hadassi | M | 59 |
The Hebrew University of Jerusalem
| - |
| Shmuel A. Ben-Sasson | M | - |
The Hebrew University of Jerusalem
| - |
| Arie Altman | M | - |
The Hebrew University of Jerusalem
| - |
| Eyal Mishani | M | - |
The Hebrew University of Jerusalem
| - |
| Dan Suesskind | M | 80 |
The Hebrew University of Jerusalem
| - |
| Avraham Baniel | M | - |
The Hebrew University of Jerusalem
| - |
| Geila Rozen | M | - |
The Hebrew University of Jerusalem
| - |
| Samuel Blumenfeld | M | 86 |
The Hebrew University of Jerusalem
| - |
| Jacob George | M | 59 |
The Hebrew University of Jerusalem
| - |
| Yaakov Naparstek | M | 75 |
The Hebrew University of Jerusalem
| - |
| Andrew L. Shapiro | M | 56 |
The Hebrew University of Jerusalem
| - |
| Amnon Shashua | M | 63 |
The Hebrew University of Jerusalem
| 22 years |
| Lawrence E. Glick | M | - |
The Hebrew University of Jerusalem
| - |
| Suhail Ayesh | M | - |
The Hebrew University of Jerusalem
| - |
| Patricia Ohana | M | - |
The Hebrew University of Jerusalem
| - |
| David Gershon | M | 59 |
The Hebrew University of Jerusalem
| 7 years |
| Oded Shoseyov | M | 67 |
The Hebrew University of Jerusalem
| 34 years |
| Yoav Aharoni | M | - |
The Hebrew University of Jerusalem
| - |
| Michael Schieber | M | - |
The Hebrew University of Jerusalem
| - |
| Menachem Magidor | M | - |
The Hebrew University of Jerusalem
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ira Weinstein | M | - |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | - |
| Doron Nevo | M | 68 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | - |
| Uri Danon | M | - |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 7 years |
| Monique Ben-Am | F | - |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 4 years |
| David Schlachet | M | 78 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | - |
| Orly Yarkoni | F | 68 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 5 years |
| Ruben Krupik | M | 72 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 1 years |
| Aviv Boim | M | 56 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 4 years |
| Nava Epstein | M | - |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | - |
| Avi Abraham Barak | M | 74 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | - |
| Gil Milner | M | 57 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Israel | 72 | 82.76% |
| United States | 16 | 18.39% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Hanoch Rappaport
- Personal Network
